pany & Its ProductsBloomberg Anywhere Remote Login
Post# of 15624
(Total Views: 369)
Posted On: 03/08/2018 10:39:20 AM
pany & Its ProductsBloomberg Anywhere Remote LoginBloomberg Terminal Demo Request
Markets
Stocks
Currencies
Fixed Income
ETFs
Commodities
Rates + Bonds
Economics
Magazine
Benchmark
Watchlist
Economic Calendar
Tech
U.S.
Global
Startups
Bloomberg Technology TV
Gadgets With Gurman
Digital Defense
Studio 1.0
Focus On: Infrastructure
Deal of the Week: Over and Out
Magic Leap Raises $461 Million From Saudis
Apple's Fourth U.S. Campus: Handicapping Where It Will Go
CN Rail Abruptly Replaces CEO, Seeking to ‘Energize’ Company
Broadcom's $117 Billion Takeover Bid for Qualcomm Faces a New Hurdle
Pursuits
Cars & Bikes
Style & Grooming
Spend
Watches & Gadgets
Food & Drinks
Travel
Real Estate
Art & Design
Brilliant Ideas
Politics
Global Risk Briefing
All Signs Point to Big Democratic Wins in 2018
Trump Takes Credit for Killing Hundreds of Regulations That Were Already Dead
How China’s Top Leaders Came Into Power
How the Populist Right Is Redrawing the Map of Europe
Opinion
View
Gadfly
Businessweek
Latest Issue
Debrief Podcast
Subscribe
Sign In
Subscribe
RECOMMENDED VIEWING
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
2018-03-08T15:31:45Z Email
Facebook
Twitter
Google+
LinkedIn
Save
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
PR Newswire
PETACH TIKVA, Israel, March 8, 2018
PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical
Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies
targeting a variety of different medical conditions and disorders, today
issued a chairman's statement to shareholders.
OWC Logo
In the light of recent events, and the numerous communications we have
received from shareholders, I would like to address this statement to the
Shareholders of OWCP (the "Company"
.
The Company is committed to building a leadership position in the medical
cannabis market and to our mission of improving patients' lives through the
development of new solutions, products and devices derived from and delivery
mechanisms for the use of medical cannabis.
We have recruited a highly skilled management team with multi-year experience
in medical cannabis, pharmaceutical development, corporate management and
capital markets.
As we have stated in our 8-K filing of today, we are neither a party to the
pending SEC action against a former adviser to the Company, nor is the Company
alleged to have been a party to nor had any knowledge of the purported scheme
by the former adviser, who is the subject of the SEC action.
The Company's management is committed to and focused on our development
programs which are continuing as per plan. These include inter alia, our
current safety trial for our cannabis cream; the approval processes to
initiate a safety trial for our oral disintegrating tablet and additional
pipeline projects.
As a management team, we are committed to building value for our shareholders
though professional, ethical and strategic management of a technology platform
that we believe will bring improved health and quality of life to millions of
patients around the world. We have recently announced the addition of our new
Chief Scientific Officer and we continue to develop the resources we believe
will bolster our endeavors in creating a great company.
Yours sincerely,
Dr. Stanley Hirsch
Chairman of the Board
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli
subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company')
conducts medical research and clinical trials to develop cannabis-based
pharmaceuticals and treatments for conditions including multiple myeloma,
psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and
dosage of medical cannabis. All OWCP research is conducted at leading Israeli
hospitals and scientific institutions and led by internationally renowned
investigators. The Company's Research Division is focused on pursuing clinical
trials evaluating the effectiveness of cannabinoids and cannabis-based
products for the treatment of various medical conditions, while its Consulting
Division is dedicated to helping governments and companies navigate complex
international cannabis regulatory frameworks.
For more information visit: http://www.owcpharma.com/.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is
defined in Section 27A of the United States Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
in this press release, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations
or intentions regarding the future. Such forward-looking statements include,
among other things, filing patent applications, product development, and
business strategy. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include,
among others, the inherent uncertainties associated with new projects and
development stage companies. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements. Although we
believe that any beliefs, plans, expectations and intentions contained in this
press release are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate. Investors should
consult all of the information set forth herein and should also refer to the
risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB:
OWCP) periodic reports filed from time-to-time with the Securities and
Exchange Commission.
Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research
Corp.
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(0)3-7582659
Cision View original
content:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-issues-chairmans-statement-to-shareholders-300610781.html
SOURCE OWC Pharmaceutical Research Corp.
Website: http://www.owcpharma.com/
Markets
Stocks
Currencies
Fixed Income
ETFs
Commodities
Rates + Bonds
Economics
Magazine
Benchmark
Watchlist
Economic Calendar
Tech
U.S.
Global
Startups
Bloomberg Technology TV
Gadgets With Gurman
Digital Defense
Studio 1.0
Focus On: Infrastructure
Deal of the Week: Over and Out
Magic Leap Raises $461 Million From Saudis
Apple's Fourth U.S. Campus: Handicapping Where It Will Go
CN Rail Abruptly Replaces CEO, Seeking to ‘Energize’ Company
Broadcom's $117 Billion Takeover Bid for Qualcomm Faces a New Hurdle
Pursuits
Cars & Bikes
Style & Grooming
Spend
Watches & Gadgets
Food & Drinks
Travel
Real Estate
Art & Design
Brilliant Ideas
Politics
Global Risk Briefing
All Signs Point to Big Democratic Wins in 2018
Trump Takes Credit for Killing Hundreds of Regulations That Were Already Dead
How China’s Top Leaders Came Into Power
How the Populist Right Is Redrawing the Map of Europe
Opinion
View
Gadfly
Businessweek
Latest Issue
Debrief Podcast
Subscribe
Sign In
Subscribe
RECOMMENDED VIEWING
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
2018-03-08T15:31:45Z Email
Google+
Save
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
PR Newswire
PETACH TIKVA, Israel, March 8, 2018
PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical
Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies
targeting a variety of different medical conditions and disorders, today
issued a chairman's statement to shareholders.
OWC Logo
In the light of recent events, and the numerous communications we have
received from shareholders, I would like to address this statement to the
Shareholders of OWCP (the "Company"
. The Company is committed to building a leadership position in the medical
cannabis market and to our mission of improving patients' lives through the
development of new solutions, products and devices derived from and delivery
mechanisms for the use of medical cannabis.
We have recruited a highly skilled management team with multi-year experience
in medical cannabis, pharmaceutical development, corporate management and
capital markets.
As we have stated in our 8-K filing of today, we are neither a party to the
pending SEC action against a former adviser to the Company, nor is the Company
alleged to have been a party to nor had any knowledge of the purported scheme
by the former adviser, who is the subject of the SEC action.
The Company's management is committed to and focused on our development
programs which are continuing as per plan. These include inter alia, our
current safety trial for our cannabis cream; the approval processes to
initiate a safety trial for our oral disintegrating tablet and additional
pipeline projects.
As a management team, we are committed to building value for our shareholders
though professional, ethical and strategic management of a technology platform
that we believe will bring improved health and quality of life to millions of
patients around the world. We have recently announced the addition of our new
Chief Scientific Officer and we continue to develop the resources we believe
will bolster our endeavors in creating a great company.
Yours sincerely,
Dr. Stanley Hirsch
Chairman of the Board
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli
subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company')
conducts medical research and clinical trials to develop cannabis-based
pharmaceuticals and treatments for conditions including multiple myeloma,
psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and
dosage of medical cannabis. All OWCP research is conducted at leading Israeli
hospitals and scientific institutions and led by internationally renowned
investigators. The Company's Research Division is focused on pursuing clinical
trials evaluating the effectiveness of cannabinoids and cannabis-based
products for the treatment of various medical conditions, while its Consulting
Division is dedicated to helping governments and companies navigate complex
international cannabis regulatory frameworks.
For more information visit: http://www.owcpharma.com/.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is
defined in Section 27A of the United States Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
in this press release, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations
or intentions regarding the future. Such forward-looking statements include,
among other things, filing patent applications, product development, and
business strategy. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include,
among others, the inherent uncertainties associated with new projects and
development stage companies. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements. Although we
believe that any beliefs, plans, expectations and intentions contained in this
press release are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate. Investors should
consult all of the information set forth herein and should also refer to the
risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB:
OWCP) periodic reports filed from time-to-time with the Securities and
Exchange Commission.
Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research
Corp.
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(0)3-7582659
Cision View original
content:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-issues-chairmans-statement-to-shareholders-300610781.html
SOURCE OWC Pharmaceutical Research Corp.
Website: http://www.owcpharma.com/
(0)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)